Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accumulated Expenses (2016 - 2025)

OptimizeRx (OPRX) has disclosed Accumulated Expenses for 16 consecutive years, with $11.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 36.59% to $11.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.6 million through Dec 2025, up 36.59% year-over-year, with the annual reading at $11.6 million for FY2025, 36.59% up from the prior year.
  • Accumulated Expenses hit $11.6 million in Q4 2025 for OptimizeRx, up from $10.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $12.5 million in Q2 2025 to a low of $869791.0 in Q1 2021.
  • Historically, Accumulated Expenses has averaged $5.0 million across 5 years, with a median of $3.0 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: plummeted 48.06% in 2021 and later skyrocketed 253.18% in 2024.
  • Year by year, Accumulated Expenses stood at $2.9 million in 2021, then fell by 10.39% to $2.6 million in 2022, then surged by 196.24% to $7.7 million in 2023, then rose by 10.12% to $8.5 million in 2024, then skyrocketed by 36.59% to $11.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for OPRX at $11.6 million in Q4 2025, $10.2 million in Q3 2025, and $12.5 million in Q2 2025.